Efficacy of behavioural lifestyle interventions for weight management of psychiatric patients;Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

Sante Mentale au Quebec

Volumn 38, Issue 1, 2013, Pages 103-118

  Bélanger, Marie Ève ^a   Provencher, Martin D ^b   Shriqui, Christian ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Mood disorders; Non pharmacological interventions; Obesity; Quality of life; Schizophrenia; Weight gain

Indexed keywords

BEHAVIOR CONTROL; HUMAN; LIFESTYLE; MENTAL DISEASE; REVIEW; WEIGHT GAIN; COMPLICATION;

BEHAVIOR CONTROL; HUMANS; LIFE STYLE; MENTAL DISORDERS; WEIGHT GAIN;

EID: 84896553210     PISSN: 03836320     EISSN: 17083923     Source Type: Journal    
DOI: 10.7202/1019188ar     Document Type: Article

References (63)

1. ADULT TREATMENT PANEL III, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), Journal of the American Medical Association, 285, 19, 2486-2497.
2. ALLISON, D. B., MACKELL, J. A., MCDONNELL, D. D., 2003, The impact of weight gain on quality of life among persons with schizophrenia, Psychiatric Services, 54, 4, 565-567.
3. Álvarez-Jiménez, M., González-Blanch, C., Vázquez-Barquero, J. L., Pérez-Iglesias, R., Martínez-García, O., Pérez-Pardal, T., Crespo-Facorro, B., 2006, Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial, Journal of Clinical Psychiatry, 67, 8, 1253-1260.
4. Álvarez-Jiménez, M., HETRICK, S. E., González-Blanch, C., GLEESON, J. F., MCGORRY, P. D., 2008, Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials, British Journal of Psychiatry, 193, 2, 101-107.
5. ANDERSON, J. W., KONZ, E. C., FREDERICH, R. C., WOOD, C. L., 2001, Longterm weight-loss maintenance: A meta-analysis of US studies, The American Journal of Clinical Nutrition, 74, 5, 579-584.
6. ARONNE, L. J., SEGAL, K. R., 2003, Weight gain in the treatment of mood disorders, Journal of Clinical Psychiatry, 64, Suppl. 8, 22-29.
7. ATMACA, M., KULOGLU, M., TEZCAN, E., USTUNDAG, B., 2003, Nizatidine treatment and its relationship with leptin levels in patients with olanzapineinduced weight gain, Human Psychopharmacology: Clinical and Experimental, 18, 6, 457-461.
8. ATMACA, M., KULOGLU, M., TEZCAN, E., USTUNDAG, B., KILIC, N., 2004, Nizatidine for the treatment of patients with quetiapine-induced weight gain, Human Psychopharmacology: Clinical and Experimental, 19, 1, 37-40.
9. BALL, M. P., COONS, V. B., BUCHANAN, R. W., 2001, A program for treating olanzapine-related weight gain, Psychiatric Services, 52, 7, 967-969.
10. BRAR, J. S., GANGULI, R., PANDINA, G., TURKOZ, I., BERRY, S., MAHMOUD, R., 2005, Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder, Journal of Clinical Psychiatry, 66, 2, 205-212.
11. BUSHE, C., HADDAD, P., PEVELER, R., PENDLEBURY, J., 2005, The role of lifestyle interventions and weight management in schizophrenia. Journal of Psychopharmacology, 19, Suppl 6, 28-35.
12. BUSTILLO, J. R., LAURIELLO, J., PARKER, K., HAMMOND, R., ROWLAND, L., BOGENSCHUTZ, M., KEITH, S., 2003, Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients, Neuropsychopharmacology, 28, 3, 527-529.
13. CZOBOR, P., VOLAVKA, J., SHEITMAN, B., LINDENMAYER, J. P., CITROME, L., MCENVOY, J., LIEBERMAN, J. A., 2002, Antipsychotic-induced weight gain and therapeutic response: A differential association, Journal of Clinical Psychopharmacology, 22, 3, 244-251.
14. DEBERDT, W., WINOKUR, A., CAVAZZONI, P. A., TRZASKOMA, Q. N., CARLSON, C. D., BYMASTER, F. P., WYENER, K., FLORIS, M., BREIER, A., 2005, Amantadine for weight gain associated with olanzapine treatment, European Neuropsychopharmacology, 15, 1, 13-21.
15. DUBISAR, B. M., STONER, S. C., REYNOLDS, J., KHAN, R., RAMLATCHMAN, L., 2004, Adverse effects of atypical antipsychotic agents and their effects on quality of life, Pharmacotherapy, 24, 7, 843-847.
16. EVANS, S., NEWTON, R., HIGGINS, S., 2005, Nutritional intervention to prevent weight gain in patients commenced on olanzapine: A randomized controlled trial, Australian and New Zealand Journal of Psychiatry, 39, 6, 479-486.
17. FAGIOLINI, A., ROY CHENGAPPA, K., 2007, Weight gain and metabolic issues of medicines used for bipolar disorder, Current Psychiatry Reports, 9, n° 6, 521-528.
18. FAGIOLINI, A., FRANK, E., SCOTT, J. A., TURKIN, S., KUPFER, D. J., 2005, Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians, Bipolar Disorders, 7, 5, 424-430.
19. FAULKNER, G., COHN, T. A., 2006, Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications, Canadian Journal of Psychiatry, 51, 8, 502-511.
20. FENTON, W. S., CHAVEZ, M. R., 2006, Medication-induced weight gain and dyslipidemia in patients with schizophrenia, The American Journal of Psychiatry, 163, 10, 1697-1704.
21. GOLDSTEIN, D. J., 1992, Beneficial health effects of modest weight loss, International Journal of Obesity and Related Metabolic Disorders, 16, 6, 397-415.
22. HAMMAN, R. F., WING, R. R., EDELSTEIN, S. L., LACHIN, J. M., BRAY, G. A., DELAHANTY, L., HOSKIN, M., KRISKA, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., REGENSTEINER, J., VENDITTI, B., Wylie-Rosett, J., 2006, Effect of weight loss with lifestyle intervention on risk of diabetes, Diabetes care, 29, 9, 2102-2107.
23. HENDERSON, D. C., COPELAND, P. M., DALEY, T. B., BORBA, C. P., CATHER, C., NGUYEN, D. D., LOUIE, P. M., EVINS, E., FREUDENREICH, O., HAYDEN, D., GOFF, D. C., 2005, A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain, The American Journal of Psychiatry, 162, 5, 954-962.
24. HESTER, E. K., THROWER, M. R., 2005, Current options in the management of olanzapine-associated weight gain, The Annals of Pharmacotherapy, 39, 2, 302-310.
25. HOLT, R. A., MAUNDER, M. W., 1996, Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy? Journal of Human Nutrition and Dietetics, 9, 2, 127-133.
26. Iglesias-García, C., Toimil-Iglesias, A., Alonso-Villa, M. J., 2010, Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia, Journal of Psychiatric and Mental Health Nursing, 17, 9, 849-851.
27. Jean-Baptiste, M., TEK, C., LISKOV, E., CHAKUNTA, U. R., NICHOLLS, S., HASSAN, A. Q., BROWNELL, K. D., WEXLER, B. E., 2007, A pilot study of a weight management program with food provision in schizophrenia, Schizophrenia Research, 96, n° 1-3, 198-205.
28. KHAZAAL, Y., FRESARD, E., RABIA, S., CHATTON, A., ROTHEN, S., POMINI, V., GRASSET, F., BORGEAT, F., ZULLINO, D., 2007, Cognitive behavioural therapy for weight gain associated with antipsychotic drugs, Schizophrenia Research, 91, 1-3, 169-177.
29. KO, Y. H., JOE, S. H., JUNG, I. K., KIM, S. H., 2005, Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain, Clinical Neuropharmacology, 28, 4, 169-175.
30. KURZTHALER, I., FLEISCHHACKER, W. W., 2001, The clinical implications of weight gain in schizophrenia, Journal of Clinical Psychiatry, 62, Suppl. 7, 32-37.
31. KWON, J. S., CHOI, J. S., BAHK, W. M., KIM, C. Y., KIM, C. H., SHIN, Y. C., PARK, B. J., OH, C. G., 2006, Weight management program for treatmentemergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-Week randomized controlled clinical trial, Journal of Clinical Psychiatry, 67, 4, 547-553.
32. LEUCHT, S., HERES, S., 2006, Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia, Journal of Clinical Psychiatry, 67, suppl 5, 3-8.
33. LITTRELL, K. H., HILLIGOSS, N. M., KIRSHNER, C. D., PETTY, R. G., JOHNSON, C. G., 2003, The effects of an educational intervention on antipsychotic-induced weight gain, Journal of Nursing Scholarship, 35, 3, 237-241.
34. MACMAHON, S., CUTLER, J., BRITTAIN, E., HIGGINS, M., 1987, Obesity and hypertension: Epidemiological and clinical issues, European Heart Journal, 8, suppl B, 57-70.
35. MAURI, M., SIMONCINI, M., CASTROGIOVANNI, S., IOVIENO, N., CECCONI, D., DELL’AGNELLO, G., QUADRIGLI, M., ROSSI, A., DONDA, P., FAGIOLINI, A., CASSANO, G. B., 2008, A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine, Pharmacopsychiatry, 41, 1, 17-23.
36. MCINTYRE, R. S., KONARSKI, J. Z., MISENER, V. L., KENNEDY, S. H., 2005, Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications, Annals of Clinical Psychiatry, 17, 2, 83-93.
37. MELAMED, Y., Stein-Reisner, O., GELKOPF, M., LEVI, G., SIVAN, T., LLIEVICI, G., ROSENBERG, R., WEIZMAN, A., BLEICH, A., 2008, Multi-modal weight control intervention for people with persistent mental disorders, Psychiatric Rehabilitation Journal, 31, 3, 194-200.
38. MELTZER, H. Y., PERRY, E., JAYATHILAKE, K., 2003, Clozapine-induced weight gain predicts improvement in psychopathology, Schizophrenia Research, 59, 1, 19-27.
39. MENZA, M., VREELAND, B., MINSKY, S., GARA, M., RADLER, D. R., SAKOWITZ, M., 2004, Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program, Journal of Clinical Psychiatry, 65, 4, 471-477.
40. NEMEROFF, C. B., 2003, Safety of available agents used to treat bipolar disorder: Focus on weight gain, Journal of Clinical Psychiatry, 64, 5, 532-539.
41. NEWCOMER, J. W., 2006, Medical risk in patients with bipolar disorder and schizophrenia, Journal of Clinical Psychiatry, 67, Suppl. 9, 25-30.
42. NHLBI OBESITY EDUCATION INITIATIVE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS, 2000, The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults: National heart, lung and blood institute, NIH Publication, 00, 4084, 1-83.
43. NHLBI OBESITY EDUCATION INITIATIVE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS, 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, NIH Publication, 98, 4083, 1-228.
44. ORGANISATION MONDIALE DE LA SANTÉ, 2003, Obésité: Prévention et prise en charge de l’épidémie mondiale, OMS, Série de rapports techniques, 894, 1-300.
45. PERKINS, D. O., 2002, Predictors of noncompliance in patients with schizophrenia, Journal of Clinical Psychiatry, 63, 12, 1121-1128.
46. POULIN, M., CHAPUT, J., SIMARD, V., VINCENT, P., BERNIER, J., GAUTHIER, Y., LANCTÔT, G., SAINDON, J., VINCENT, A., GAGNON, S., TREMBLAY, A., 2007, Management of antipsychotic-induced weight gain: Prospective naturalistic study of the effectiveness of a supervised exercise programme, Australian and New Zealand Journal of Psychiatry, 41, 12, 980-989.
47. POYUROVSKY, M., ISAACS, I., FUCHS, C., SCHNEIDMAN, M., FARAGIAN, S., WEIZMAN, R., WEIZMAN, A., 2003, Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study, The American Journal of Psychiatry, 160, 2, 297-302.
48. POYUROVSKY, M., PASHINIAN, A., Gil-Ad, I., MAAYAN, R., SCHNEIDMAN, M., FUCHS, C., WEIZMAN, A., 2002, Olanzapine-induced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine, The American Journal of Psychiatry, 159, 6, 1058-1060.
49. POYUROVSKY, M., TAL, V., MAAYAN, R., Gil-Ad, I., FUCHS, C., WEIZMAN, A., 2004, The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: A double-blind placebocontrolled pilot study, European Neuropsychopharmacology, 14, 4, 332-336.
50. ROY CHENGAPPA, R., CHALASANI, L., BRAR, J. S., PAREPALLY, H., HOUCK, P., LEVINE, J., 2002, Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An openlabel, nonrandomized chart review, Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, 24, 10, 1576-1584.
51. SCHWARTZ, T. L., NIHALANI, N., VIRK, S., JINDAL, S., CHILTON, M., 2004, Psychiatric medication-induced obesity: Treatment options, Obesity Reviews, 5, 4, 233-238.
52. SCOTT, J., POPE, M., 2002, Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization, The American Journal of Psychiatry, 159, 11, 1927-1929.
53. SEIDELL, J. C., 1998, Societal and personal costs of obesity, Experimental and Clinical Endocrinology and Diabetes, 106, Suppl. 2, 7-9.
54. STONE, N. J., SAXON, D., 2005, Approach to treatment of the patient with metabolic syndrome: Lifestyle therapy, The American Journal of Cardiology, 96, 4, Suppl. 1, 15-21.
55. THOMAS, P. R., 1995, Weighing the options: Criteria for evaluating weightmanagement programs, National Academies Press, Washington DC.
56. UMBRICHT, D. S. G., POLLACK, S., KANE, J. M., 1994, Clozapine and weight gain, Journal of Clinical Psychiatry, 55, Suppl. B, 157-160.
57. VREELAND, B., MINSKY, S., MENZA, M., RADLER RIGASSIO, D., ROEMHELDHAMM, B., STERN, R., 2003, A program for managing weight gain associated with atypical antipsychotics, Psychiatric Services, 54, 8, 1155-1157.
58. WEBER, M., WYNE, K., 2006, A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics, Schizophrenia Research, 83, 1, 95-101.
59. WEIDEN, P., RADULOVIC, L., WANG, C., ALLISON, D., 2003, Sibutramine for the treatment of obesity in schizophrenia: Randomized, placebo controlled pilot study, Paper presented at the American Psychiatric Association Annual Meeting, San Fransisco (CA).
60. WILDES, J. E., MARCUS, M. D., FAGIOLINI, A., 2006, Obesity in patients with bipolar disorder: A biopsychosocial-behavioral model, Journal of Clinical Psychiatry, 67, 6, 904-915.
61. WIRSHING, D. A., 2004, Schizophrenia and obesity: Impact of antipsychotic medications, Journal of Clinical Psychiatry, 65, Suppl. 18, 13-26.
62. WU, R. R., ZHAO, J. P., JIN, H., SHAO, P., FANG, M. S., GUO, X. F., HE, Y. Q., LIU, Y. J., CHEN, J. D., LI, L.-H., 2008, Lifestyle intervention and metformin for the treatment of antipsychotic-induced weight gain: A randomized controlled trial, Journal of the American Medical Association, 299, 2, 185-193.
63. ZIMMERMANN, U., KRAUS, T., HIMMERICH, H., SCHULD, A., POLLMÄCHER, T., 2003, Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients, Journal of Psychiatric Research, 37, 3, 193-220.